By Ben Glickman Acasti Pharma said Friday it would affect a one-for-six reverse stock split in order to regain compliance with the Nasdaq Capital Market's.
Acasti Pharma Inc. announced that the Company has aligned with the U.S. Food and Drug Administration on the protocol for its pivotal Phase 3 trial of GTX-104 and the FDA also provided guidance for a.
By Robb M. Stewart Acasti Pharma said Wednesday it has aligned with the U.S. Food and Drug Administration on the protocol for its late-stage trial of its lead clinical asset, GTX-104. The.
Acasti Pharma (NASDAQ:ACST – Get Rating) is scheduled to issue its quarterly earnings data on Monday, June 19th. Acasti Pharma Price Performance Shares of ACST stock opened at $0.58 on Friday. The company’s fifty day moving average price is $0.49 and its two-hundred day moving average price is $0.53. The firm has a market capitalization […]